Cargando…
A pancancer analysis of the oncogenic role of ZNRF2 in human tumours
Finding effective treatments for cancer requires a thorough understanding of how it develops and progresses. Recent research has revealed the crucial role that Zinc and ring finger 2 (ZNRF2) play in the progression of non‐small cell lung cancer (NSCLC) by controlling cell growth and death. However,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623518/ https://www.ncbi.nlm.nih.gov/pubmed/37551845 http://dx.doi.org/10.1111/jcmm.17900 |
_version_ | 1785130755142189056 |
---|---|
author | Shi, Fujie Wu, Yunfei Wang, Kai Wang, Jiafan Liu, Minghui Sun, Xinlei |
author_facet | Shi, Fujie Wu, Yunfei Wang, Kai Wang, Jiafan Liu, Minghui Sun, Xinlei |
author_sort | Shi, Fujie |
collection | PubMed |
description | Finding effective treatments for cancer requires a thorough understanding of how it develops and progresses. Recent research has revealed the crucial role that Zinc and ring finger 2 (ZNRF2) play in the progression of non‐small cell lung cancer (NSCLC) by controlling cell growth and death. However, a comprehensive analysis of ZNRF2's role in cancer as a whole has yet to be conducted. Our study sought to investigate the impact of ZNRF2 on diverse human tumours, as well as the molecular pathways involved, using databases such as TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus) and the Human Protein Atlas (HPA), as well as several bioinformatic tools. Our findings indicate that ZNRF2 is generally expressed at higher levels in tumours than in normal tissues, and in some cancers, its levels correlate positively with disease stage, potentially predicting a poor prognosis for patients. We also discovered genetic changes in ZNRF2 among cancer patients, as well as its relationship with cancer‐related fibroblasts, endothelial cells and immune cell infiltration. Additionally, we explored potential molecular mechanisms of ZNRF2 in tumours, finding that it increases in hepatocellular carcinoma (HCC) tissues and that inhibiting its expression through ZNRF2 siRNA can limit HepG2 cell proliferation. Overall, our study provides a comprehensive overview of ZNRF2's oncogenic roles across various cancers. |
format | Online Article Text |
id | pubmed-10623518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106235182023-11-04 A pancancer analysis of the oncogenic role of ZNRF2 in human tumours Shi, Fujie Wu, Yunfei Wang, Kai Wang, Jiafan Liu, Minghui Sun, Xinlei J Cell Mol Med Original Articles Finding effective treatments for cancer requires a thorough understanding of how it develops and progresses. Recent research has revealed the crucial role that Zinc and ring finger 2 (ZNRF2) play in the progression of non‐small cell lung cancer (NSCLC) by controlling cell growth and death. However, a comprehensive analysis of ZNRF2's role in cancer as a whole has yet to be conducted. Our study sought to investigate the impact of ZNRF2 on diverse human tumours, as well as the molecular pathways involved, using databases such as TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus) and the Human Protein Atlas (HPA), as well as several bioinformatic tools. Our findings indicate that ZNRF2 is generally expressed at higher levels in tumours than in normal tissues, and in some cancers, its levels correlate positively with disease stage, potentially predicting a poor prognosis for patients. We also discovered genetic changes in ZNRF2 among cancer patients, as well as its relationship with cancer‐related fibroblasts, endothelial cells and immune cell infiltration. Additionally, we explored potential molecular mechanisms of ZNRF2 in tumours, finding that it increases in hepatocellular carcinoma (HCC) tissues and that inhibiting its expression through ZNRF2 siRNA can limit HepG2 cell proliferation. Overall, our study provides a comprehensive overview of ZNRF2's oncogenic roles across various cancers. John Wiley and Sons Inc. 2023-08-08 /pmc/articles/PMC10623518/ /pubmed/37551845 http://dx.doi.org/10.1111/jcmm.17900 Text en © 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Shi, Fujie Wu, Yunfei Wang, Kai Wang, Jiafan Liu, Minghui Sun, Xinlei A pancancer analysis of the oncogenic role of ZNRF2 in human tumours |
title | A pancancer analysis of the oncogenic role of ZNRF2 in human tumours |
title_full | A pancancer analysis of the oncogenic role of ZNRF2 in human tumours |
title_fullStr | A pancancer analysis of the oncogenic role of ZNRF2 in human tumours |
title_full_unstemmed | A pancancer analysis of the oncogenic role of ZNRF2 in human tumours |
title_short | A pancancer analysis of the oncogenic role of ZNRF2 in human tumours |
title_sort | pancancer analysis of the oncogenic role of znrf2 in human tumours |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623518/ https://www.ncbi.nlm.nih.gov/pubmed/37551845 http://dx.doi.org/10.1111/jcmm.17900 |
work_keys_str_mv | AT shifujie apancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT wuyunfei apancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT wangkai apancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT wangjiafan apancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT liuminghui apancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT sunxinlei apancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT shifujie pancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT wuyunfei pancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT wangkai pancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT wangjiafan pancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT liuminghui pancanceranalysisoftheoncogenicroleofznrf2inhumantumours AT sunxinlei pancanceranalysisoftheoncogenicroleofznrf2inhumantumours |